Companies
Ferring Pharmaceuticals
Rebyota (RBX2660) — First-in-world approved microbiota liquid enema.
- Country
- Switzerland
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | €121 million payment related to the Rebyota approval and settlement agreement with previous shareholders of Rebiotix Inc (acquired in 2018) | ferring.com |
| Production site | dedicated U.S. manufacturing facility; Rebiotix, Inc. facility in Roseville, MN; and dedicated gene therapy drug product facility at Parsippany, New Jersey | ferringusa.com |
| Regulatory approval | FDA approved in 2022; Health Canada authorized on March 5, 2025 | businesswire.com · ferring.ca · ferring.com |
| Headcount | More than 7,000 people (global, as of 2024); more than 7,500 (global, as of 2025); more than 900 (U.S., as of 2025) | businesswire.com · ferring.com |
| Revenue | Total global revenues of €2,343 million (2024); over €2.5 billion (2025) | businesswire.com · ferring.com |
Independent sources: businesswire.com · ferringusa.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Microbiome therapeutics (live biotherapeutic products) | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.